Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
if (Configure::read('debug')) {
trigger_error($message, E_USER_WARNING);
} else {
$response = object(Cake\Http\Response) {
'status' => (int) 200,
'contentType' => 'text/html',
'headers' => [
'Content-Type' => [
[maximum depth reached]
]
],
'file' => null,
'fileRange' => [],
'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
'cacheDirectives' => [],
'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-trace').style.display = (document.getElementById('cakeErr67f7fdd01138c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f7fdd01138c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-code').style.display = (document.getElementById('cakeErr67f7fdd01138c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-context').style.display = (document.getElementById('cakeErr67f7fdd01138c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f7fdd01138c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">>
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/>
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/>
</span></span></code></pre><pre id="cakeErr67f7fdd01138c-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
'article_current' => object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
[maximum depth reached]
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
[maximum depth reached]
],
'[dirty]' => [[maximum depth reached]],
'[original]' => [[maximum depth reached]],
'[virtual]' => [[maximum depth reached]],
'[hasErrors]' => false,
'[errors]' => [[maximum depth reached]],
'[invalid]' => [[maximum depth reached]],
'[repository]' => 'Articles'
},
'articleid' => (int) 21164,
'metaTitle' => 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies',
'metaKeywords' => 'medicines,generic drugs,Ranbaxy,Health',
'metaDesc' => '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...',
'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>',
'lang' => 'English',
'SITE_URL' => 'https://im4change.in/',
'site_title' => 'im4change',
'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
(int) 0 => object(Cake\ORM\Entity) {},
(int) 1 => object(Cake\ORM\Entity) {},
(int) 2 => object(Cake\ORM\Entity) {},
(int) 3 => object(Cake\ORM\Entity) {}
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
'*' => true,
'id' => false
],
'[dirty]' => [],
'[original]' => [],
'[virtual]' => [],
'[hasErrors]' => false,
'[errors]' => [],
'[invalid]' => [],
'[repository]' => 'Articles'
}
$articleid = (int) 21164
$metaTitle = 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies'
$metaKeywords = 'medicines,generic drugs,Ranbaxy,Health'
$metaDesc = '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drugs-ranbaxy-and-lies-21309.html"/>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
media="all"/>
<title>LATEST NEWS UPDATES | Drugs, Ranbaxy and lies | Im4change.org</title>
<meta name="description" content="
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for..."/>
<script src="https://im4change.in/js/jquery-1.10.2.js"></script>
<script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
<script language="javascript" type="text/javascript">
$(document).ready(function () {
var img = $("img")[0]; // Get my img elem
var pic_real_width, pic_real_height;
$("<img/>") // Make in memory copy of image to avoid css issues
.attr("src", $(img).attr("src"))
.load(function () {
pic_real_width = this.width; // Note: $(this).width() will not
pic_real_height = this.height; // work for in memory images.
});
});
</script>
<style type="text/css">
@media screen {
div.divFooter {
display: block;
}
}
@media print {
.printbutton {
display: none !important;
}
}
</style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
<tr>
<td class="top_bg">
<div class="divFooter">
<img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
</div>
</td>
</tr>
<tr>
<td id="topspace"> </td>
</tr>
<tr id="topspace">
<td> </td>
</tr>
<tr>
<td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
<form><input type="button" value=" Print this page "
onclick="window.print();return false;"/></form>
</td>
</tr>
<tr>
<td width="100%">
<h1 class="news_headlines" style="font-style:normal">
<strong>Drugs, Ranbaxy and lies</strong></h1>
</td>
</tr>
<tr>
<td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p> </font>
</td>
</tr>
<tr>
<td> </td>
</tr>
<tr>
<td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
<form><input type="button" value=" Print this page "
onclick="window.print();return false;"/></form>
</td>
</tr>
</table></body>
</html>'
}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
$response = object(Cake\Http\Response) {
'status' => (int) 200,
'contentType' => 'text/html',
'headers' => [
'Content-Type' => [
[maximum depth reached]
]
],
'file' => null,
'fileRange' => [],
'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
'cacheDirectives' => [],
'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-trace').style.display = (document.getElementById('cakeErr67f7fdd01138c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f7fdd01138c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-code').style.display = (document.getElementById('cakeErr67f7fdd01138c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-context').style.display = (document.getElementById('cakeErr67f7fdd01138c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f7fdd01138c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">>
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/>
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/>
</span></span></code></pre><pre id="cakeErr67f7fdd01138c-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
'article_current' => object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
[maximum depth reached]
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
[maximum depth reached]
],
'[dirty]' => [[maximum depth reached]],
'[original]' => [[maximum depth reached]],
'[virtual]' => [[maximum depth reached]],
'[hasErrors]' => false,
'[errors]' => [[maximum depth reached]],
'[invalid]' => [[maximum depth reached]],
'[repository]' => 'Articles'
},
'articleid' => (int) 21164,
'metaTitle' => 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies',
'metaKeywords' => 'medicines,generic drugs,Ranbaxy,Health',
'metaDesc' => '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...',
'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>',
'lang' => 'English',
'SITE_URL' => 'https://im4change.in/',
'site_title' => 'im4change',
'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
(int) 0 => object(Cake\ORM\Entity) {},
(int) 1 => object(Cake\ORM\Entity) {},
(int) 2 => object(Cake\ORM\Entity) {},
(int) 3 => object(Cake\ORM\Entity) {}
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
'*' => true,
'id' => false
],
'[dirty]' => [],
'[original]' => [],
'[virtual]' => [],
'[hasErrors]' => false,
'[errors]' => [],
'[invalid]' => [],
'[repository]' => 'Articles'
}
$articleid = (int) 21164
$metaTitle = 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies'
$metaKeywords = 'medicines,generic drugs,Ranbaxy,Health'
$metaDesc = '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drugs-ranbaxy-and-lies-21309.html"/>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
media="all"/>
<title>LATEST NEWS UPDATES | Drugs, Ranbaxy and lies | Im4change.org</title>
<meta name="description" content="
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for..."/>
<script src="https://im4change.in/js/jquery-1.10.2.js"></script>
<script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
<script language="javascript" type="text/javascript">
$(document).ready(function () {
var img = $("img")[0]; // Get my img elem
var pic_real_width, pic_real_height;
$("<img/>") // Make in memory copy of image to avoid css issues
.attr("src", $(img).attr("src"))
.load(function () {
pic_real_width = this.width; // Note: $(this).width() will not
pic_real_height = this.height; // work for in memory images.
});
});
</script>
<style type="text/css">
@media screen {
div.divFooter {
display: block;
}
}
@media print {
.printbutton {
display: none !important;
}
}
</style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
<tr>
<td class="top_bg">
<div class="divFooter">
<img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
</div>
</td>
</tr>
<tr>
<td id="topspace"> </td>
</tr>
<tr id="topspace">
<td> </td>
</tr>
<tr>
<td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
<form><input type="button" value=" Print this page "
onclick="window.print();return false;"/></form>
</td>
</tr>
<tr>
<td width="100%">
<h1 class="news_headlines" style="font-style:normal">
<strong>Drugs, Ranbaxy and lies</strong></h1>
</td>
</tr>
<tr>
<td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p> </font>
</td>
</tr>
<tr>
<td> </td>
</tr>
<tr>
<td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
<form><input type="button" value=" Print this page "
onclick="window.print();return false;"/></form>
</td>
</tr>
</table></body>
</html>'
}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
$response = object(Cake\Http\Response) {
'status' => (int) 200,
'contentType' => 'text/html',
'headers' => [
'Content-Type' => [
[maximum depth reached]
]
],
'file' => null,
'fileRange' => [],
'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
'cacheDirectives' => [],
'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-trace').style.display = (document.getElementById('cakeErr67f7fdd01138c-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f7fdd01138c-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-code').style.display = (document.getElementById('cakeErr67f7fdd01138c-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7fdd01138c-context').style.display = (document.getElementById('cakeErr67f7fdd01138c-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f7fdd01138c-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700"><</span><span style="color: #0000BB">head</span><span style="color: #007700">>
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000"> <link rel="canonical" href="<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">); </span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">category</span><span style="color: #007700">-></span><span style="color: #0000BB">slug</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>/<span style="color: #0000BB"><?php </span><span style="color: #007700">echo </span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-></span><span style="color: #0000BB">seo_url</span><span style="color: #007700">; </span><span style="color: #0000BB">?></span>.html"/>
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB"> </span><span style="color: #007700"><</span><span style="color: #0000BB">meta http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type" </span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html; charset=utf-8"</span><span style="color: #007700">/>
</span></span></code></pre><pre id="cakeErr67f7fdd01138c-context" class="cake-context" style="display: none;">$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
'article_current' => object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
[maximum depth reached]
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
[maximum depth reached]
],
'[dirty]' => [[maximum depth reached]],
'[original]' => [[maximum depth reached]],
'[virtual]' => [[maximum depth reached]],
'[hasErrors]' => false,
'[errors]' => [[maximum depth reached]],
'[invalid]' => [[maximum depth reached]],
'[repository]' => 'Articles'
},
'articleid' => (int) 21164,
'metaTitle' => 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies',
'metaKeywords' => 'medicines,generic drugs,Ranbaxy,Health',
'metaDesc' => '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...',
'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>',
'lang' => 'English',
'SITE_URL' => 'https://im4change.in/',
'site_title' => 'im4change',
'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
(int) 0 => object(Cake\ORM\Entity) {},
(int) 1 => object(Cake\ORM\Entity) {},
(int) 2 => object(Cake\ORM\Entity) {},
(int) 3 => object(Cake\ORM\Entity) {}
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
'*' => true,
'id' => false
],
'[dirty]' => [],
'[original]' => [],
'[virtual]' => [],
'[hasErrors]' => false,
'[errors]' => [],
'[invalid]' => [],
'[repository]' => 'Articles'
}
$articleid = (int) 21164
$metaTitle = 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies'
$metaKeywords = 'medicines,generic drugs,Ranbaxy,Health'
$metaDesc = '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drugs-ranbaxy-and-lies-21309.html"/>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
media="all"/>
<title>LATEST NEWS UPDATES | Drugs, Ranbaxy and lies | Im4change.org</title>
<meta name="description" content="
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for..."/>
<script src="https://im4change.in/js/jquery-1.10.2.js"></script>
<script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
<script language="javascript" type="text/javascript">
$(document).ready(function () {
var img = $("img")[0]; // Get my img elem
var pic_real_width, pic_real_height;
$("<img/>") // Make in memory copy of image to avoid css issues
.attr("src", $(img).attr("src"))
.load(function () {
pic_real_width = this.width; // Note: $(this).width() will not
pic_real_height = this.height; // work for in memory images.
});
});
</script>
<style type="text/css">
@media screen {
div.divFooter {
display: block;
}
}
@media print {
.printbutton {
display: none !important;
}
}
</style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
<tr>
<td class="top_bg">
<div class="divFooter">
<img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
</div>
</td>
</tr>
<tr>
<td id="topspace"> </td>
</tr>
<tr id="topspace">
<td> </td>
</tr>
<tr>
<td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
<form><input type="button" value=" Print this page "
onclick="window.print();return false;"/></form>
</td>
</tr>
<tr>
<td width="100%">
<h1 class="news_headlines" style="font-style:normal">
<strong>Drugs, Ranbaxy and lies</strong></h1>
</td>
</tr>
<tr>
<td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p> </font>
</td>
</tr>
<tr>
<td> </td>
</tr>
<tr>
<td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
<form><input type="button" value=" Print this page "
onclick="window.print();return false;"/></form>
</td>
</tr>
</table></body>
</html>'
}
$cookies = []
$values = [
(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39
Notice (8): Undefined variable: urlPrefix [APP/Template/Layout/printlayout.ctp, line 8]
$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
'article_current' => object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
[maximum depth reached]
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
[maximum depth reached]
],
'[dirty]' => [[maximum depth reached]],
'[original]' => [[maximum depth reached]],
'[virtual]' => [[maximum depth reached]],
'[hasErrors]' => false,
'[errors]' => [[maximum depth reached]],
'[invalid]' => [[maximum depth reached]],
'[repository]' => 'Articles'
},
'articleid' => (int) 21164,
'metaTitle' => 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies',
'metaKeywords' => 'medicines,generic drugs,Ranbaxy,Health',
'metaDesc' => '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...',
'disp' => '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>',
'lang' => 'English',
'SITE_URL' => 'https://im4change.in/',
'site_title' => 'im4change',
'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {
'id' => (int) 21164,
'title' => 'Drugs, Ranbaxy and lies',
'subheading' => '',
'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
<br />
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
</p>
<p align="justify">
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
</p>',
'credit_writer' => 'The Hindu, 29 May, 2013, http://www.thehindu.com/opinion/editorial/drugs-ranbaxy-and-lies/article4760215.ece',
'article_img' => '',
'article_img_thumb' => '',
'status' => (int) 1,
'show_on_home' => (int) 1,
'lang' => 'EN',
'category_id' => (int) 16,
'tag_keyword' => '',
'seo_url' => 'drugs-ranbaxy-and-lies-21309',
'meta_title' => null,
'meta_keywords' => null,
'meta_description' => null,
'noindex' => (int) 0,
'publish_date' => object(Cake\I18n\FrozenDate) {},
'most_visit_section_id' => null,
'article_big_img' => null,
'liveid' => (int) 21309,
'created' => object(Cake\I18n\FrozenTime) {},
'modified' => object(Cake\I18n\FrozenTime) {},
'edate' => '',
'tags' => [
(int) 0 => object(Cake\ORM\Entity) {},
(int) 1 => object(Cake\ORM\Entity) {},
(int) 2 => object(Cake\ORM\Entity) {},
(int) 3 => object(Cake\ORM\Entity) {}
],
'category' => object(App\Model\Entity\Category) {},
'[new]' => false,
'[accessible]' => [
'*' => true,
'id' => false
],
'[dirty]' => [],
'[original]' => [],
'[virtual]' => [],
'[hasErrors]' => false,
'[errors]' => [],
'[invalid]' => [],
'[repository]' => 'Articles'
}
$articleid = (int) 21164
$metaTitle = 'LATEST NEWS UPDATES | Drugs, Ranbaxy and lies'
$metaKeywords = 'medicines,generic drugs,Ranbaxy,Health'
$metaDesc = '
-The Hindu
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for...'
$disp = '<div align="justify">-The Hindu</div><p align="justify"><br /> Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.</p><p align="justify">Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'
include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed to meet specifications and making intentionally false statements to the government. These are serious charges against any company, not to talk of one from the critical industry of pharmaceuticals, whose products are responsible for curing illnesses and ensuring the well-being of humankind itself. In the event, it is indeed surprising that Ranbaxy managed to get away with a fine of just $500 million. If the charges of the whistle-blower, Dinesh Thakur, are to be believed, Ranbaxy is guilty of not just failing to follow good manufacturing practices as prescribed by the FDA but of outright fraud. The company's actions are a breach of the sacred trust that patients, whether foreign or Indian, place in it when they buy its drugs. The company deserves to be penalised more severely; at its harshest it could even include blacklisting of its drugs pending investigation.
Yet the fact on the ground is that the Indian government has done precious little to either probe or act against the company since the misdemeanour first came to light. As recently as in November, Ranbaxy was forced to withdraw its anti-cholesterol drug from the American market after some batches were found to be contaminated with glass powder. It is a reflection of the state of governance prevailing now that even after this, and Ranbaxy's admission of guilt, neither the government nor the regulator - the Drug Controller General of India - has announced a probe into the company. Even assuming that Ranbaxy has mended its ways, don't consumers need reassurance of the same and is it not the government's responsibility to provide that after suitable investigation? The Ranbaxy fraud raises two vital issues. First, about the quality and efficacy of drugs produced not just by that company but by the entire pharmaceuticals industry in India. We need robust regulation of the sector, including of surprise checks and visits to production facilities to reassure ourselves. Second, about the consequences for India's fast-growing generic drugs export industry. Ranbaxy-like episodes will not only set back the fortunes of the export industry but also give a handle to multinational pharmaceutical companies - no angels themselves - in their endeavour to push their patented, branded drugs as opposed to the cheaper, generic versions.
